Although more decisions are to be made, they at least have a name, a board chair, and a general location for their headquarters once Vectrus and Vertex merge later this year. The combination of ...
Vertex Pharmaceuticals' pain relief program could be lucrative in the years ahead. Phase 3 clinical trials suggest the current medicine is likely to be approved for sale. Investors' high expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback